Pre-clinical studies

There has been a significant amount of pre-clinical investigation on the use of CytoSorb for the treatment of sepsis, particularly in rat cecal ligation puncture and lethal endotoxin models of sepsis.  A tremendous amount of insight, correlating cytokine reduction with improvements in survival and other physiologic parameters, has been obtained.  In particular, there have been new exciting insights on how CytoSorb treatment can prevent cell-mediated organ injury by re-directing activated leukocytes to the site of infection and away from otherwise healthy organs.  In addition, there have been studies demonstrating the ability of CytoSorb to remove bacterial exotoxins like S. aureus alpha hemolysin, a new strategy in the fight against sepsis.  Find below the main pre-clinical publications on the CytoSorb technology and therapy: